Efficacy Trial of Oral Tetrahydrocannabinol in Patients With Fibromyalgia
Unknown statusNot applicableNCT01149018
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The objective of the study is to evaluate the effectiveness of oral tetrahydrocannabinol in patients suffering from Fibromyalgia
Study details
- Official title
- A Randomized, Double-blind, Placebo-controlled Trial of Oral Tetrahydrocannabinol (∆-9-THC) in Patients With Fibromyalgia
- Conditions
- Interventions
- Drug: Tetrahydrocannabinol
- Drug: Placebo
- Sponsor
- Hadassah Medical Organization
- Collaborators
- Hebrew University of Jerusalem
- Start date
- 2010-06
- Primary completion
- 2012-07
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Israel
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: \- Adult (\>18y.o) Patient with Fibromyalgia, diagnosed by ACR criteria Exclusion Criteria: \- Children \< 18 years old Patients with following psychiatric disorders: * Psychosis or history of acute psychosis * Schizophrenia * Bipolar disorder Patients smoking marijuana, using hashish or any other form of cannabis. Patients with history of drug abuse or illicit drug use Patients receiving chronic treatment with strong opioids (Morphine, Oxycodone, Fentanyl, Methadone, Hydromorphone, Buprenorphine, Pethidine). Weak opioids as Tramadol or Propoxyphene will be allowed. Pregnant patients
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01149018